Vaclava Polivkova Peter Rohon Hana Klamova Olga Cerna Martina Divoka Nikola Curik Jan Zach Martin Novak Iuri Marinov Simona Soverini Edgar Faber Katerina Machova Polakova
10.1371/journal.pone.0155959
PLoS One
2016 May 23;11(5):e0155959.
CC BY
https://pubmed.ncbi.nlm.nih.gov/27214026/
Fusion Proteins, bcr-abl / genetics Interferon-alpha / administration & dosage Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Protein Kinase Inhibitors / administration & dosage
Fusion Proteins, bcr-abl / genetics Interferon-alpha / administration & dosage Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Protein Kinase Inhibitors / administration & dosage Case Reports Research Support, Non-U.S. Gov't Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols / administration & dosage Antineoplastic Combined Chemotherapy Protocols / pharmacology Female Fusion Proteins, bcr-abl / drug effects High-Throughput Nucleotide Sequencing / methods Humans Interferon-alpha / pharmacology Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics Male Middle Aged Precision Medicine Protein Kinase Inhibitors / pharmacology Treatment Outcome Young Adult BCR-ABL1 fusion protein, human Interferon-alpha Protein Kinase Inhibitors Fusion Proteins, bcr-abl
PMC4877000
27214026
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients
2016